Expertise in
14
conditions

Dr. Sandra M. Johnson

Dermatology
5921 Riley Park Dr, 
Fort Smith, AR 
Accepting New Patients
Expertise in
14
conditions
5921 Riley Park Dr, 
Fort Smith, AR 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sandra Johnson is a Dermatologist in Fort Smith, Arkansas. Dr. Johnson is highly rated in 14 conditions, according to our data. Her top areas of expertise are Acne, Rosacea, Plaque Psoriasis, and Actinic Keratosis. Dr. Johnson is currently accepting new patients.

Her clinical research consists of co-authoring 28 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Dermatology
Licenses
Dermatology in AR
Hospital Affiliations
Baptist Health - Fort Smith
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
HMO Partners
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

JOHNSON DERMATOLOGY CLINIC PLLC
5921 Riley Park Dr, Fort Smith, AR 72916

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: June 15, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: April 11, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 2/Phase 3
A Pragmatic Trial of Home Versus Office Based Narrow Band Ultraviolet B Phototherapy for the Treatment of Psoriasis
A Pragmatic Trial of Home Versus Office Based Narrow Band Ultraviolet B Phototherapy for the Treatment of Psoriasis
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: November 30, 2022
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Enrollment Status: Completed
Publish Date: November 20, 2020
Intervention Type: Drug
Study Phase: Phase 3
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
Enrollment Status: Completed
Publish Date: June 04, 2019
Intervention Type: Other, Biological
Study Phase: Phase 2
View 8 Less Clinical Trials

28 Total Publications

Randomized Phase IIa Trial of Purified Candida Antigen for Common Warts: Evaluating the Safety and Efficacy Across Multiple Dosing Regimens.
Randomized Phase IIa Trial of Purified Candida Antigen for Common Warts: Evaluating the Safety and Efficacy Across Multiple Dosing Regimens.
Journal: Dermatology and therapy
Published: February 12, 2025
Similar Doctors
Expertise in
19
conditions
Dr. George L. Lewis
Dermatology
Expertise in
19
conditions
Dr. George L. Lewis
Dermatology

The Dermatology Center PLLC

1500 Dodson Ave, Suite 270, 
Fort Smith, AR 
 (7.4 mi)
479-709-7340
Languages Spoken:
English
See accepted insurances
Accepting New Patients

George Lewis is a Dermatologist in Fort Smith, Arkansas. Dr. Lewis is highly rated in 19 conditions, according to our data. His top areas of expertise are Aseptic and Alopecic Nodules of Scalp (AANS), Basal Cell Skin Cancer, Squamous Cell Skin Carcinoma, and Actinic Keratosis. Dr. Lewis is currently accepting new patients.

Expertise in
26
conditions
Dr. Phillip C. Stites
Dermatology
Expertise in
26
conditions
Dr. Phillip C. Stites
Dermatology

The Dermatology Center PLLC

7900 Dallas St, 
Fort Smith, AR 
 (5.8 mi)
479-242-6647
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Phillip Stites is a Dermatologist in Fort Smith, Arkansas. Dr. Stites is highly rated in 26 conditions, according to our data. His top areas of expertise are Seborrheic Keratosis, Warts, Actinic Keratosis, and Sunburn. Dr. Stites is currently accepting new patients.

Expertise in
13
conditions
Dr. Mark F. Naylor
Dermatology
Expertise in
13
conditions
Dr. Mark F. Naylor
Dermatology

Advanced Dermatology And Skin Cancer Center, LLC

1444 E Stearns St, Suite 11, 
Fayetteville, AR 
 (60.2 mi)
479-718-7546
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Mark Naylor is a Dermatologist in Fayetteville, Arkansas. Dr. Naylor is highly rated in 13 conditions, according to our data. His top areas of expertise are Pompholyx Eczema, Basal Cell Skin Cancer, GAPO Syndrome, and Atopic Dermatitis. Dr. Naylor is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Johnson's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 32 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile